NCT00571519终止3 期
A Randomized, Double-blind, Placebo, and Active Comparator-controlled, Parallel-group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 94
- 主要终点
- Change in A1c From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus
研究概览
简要总结
This is a 26-week, multicenter, randomized, double-blind, placebo and active comparator-controlled, parallel-group study in participants with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. Pioglitazone is used as active comparator. The total duration of a participant's participation will be approximately 30 weeks, including a 2-week placebo lead-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period. Participants who complete the randomized portion of the study per protocol may have the opportunity to continue in a long-term extension study of active treatments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provided written informed consent at screening.
- •Diagnosed with type 2 diabetes mellitus.
- •Glycosylated hemoglobin (A1c) >7.0% and ≤8.5% at screening.
- •Male or female ≥18 years of age.
- •Women of childbearing potential must have been using an adequate method of contraception to avoid pregnancy throughout the study, and for up to 4 weeks after study completion.
- •Fasting C-peptide level >0.5 ng/mL at screening.
- •Currently being treated with a stable dose of an approved non-thiazolidinedione antihyperglycemic medication (including sulfonylureas, meglitinides, insulin secretagogues, metformin, or α-glucosidase inhibitors) given as monotherapy, for at least 3 months prior to screening, and could discontinue that antihyperglycemic medication at Visit 2 (Week -2) and for the duration of the study. OR
- •Untreated and had not taken any antihyperglycemic agent during the 2 months prior to screening; if not treated with an oral antihyperglycemic agent, the participant was considered by the investigator to have failed diet and exercise modification as the sole treatment for type 2 diabetes mellitus.
- •Clinically stable in regard to medical conditions other than type 2 diabetes mellitus.
- •Concomitant medications (other than oral antihyperglycemic agents) were at stable doses for at least 30 days prior to enrollment and were not anticipated to need adjustment during the study period.
排除标准
- •History of type 1 diabetes and/or history of ketoacidosis.
- •History of long-term (>2 months) therapy with insulin.
- •History of prior treatment failure with, or intolerance of, a thiazolidinedione (ie, rosiglitazone, troglitazone, or pioglitazone).
- •Treatment with a fibrate lipid-lowering agent (eg, fenofibrate, gemfibrozil).
- •Confirmed repeat fasting glucose (≥2 readings of fasting blood glucose) >240 mg/dL (13.3 mmol/L) during the 2-week washout/stabilization and placebo run-in period (Period A).
- •Body mass index (BMI) >45 kg/m2 at screening.
- •History of weight loss >10% over the 3 months prior to screening.
- •Female participant who was pregnant or breastfeeding.
- •Systolic blood pressure ≥180 mmHg and/or diastolic blood pressure
- •Any known history of congestive heart failure prior to screening.
- •History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack, or any revascularization within 6 months prior to screening. History of malignancy (except participants who had been disease-free for >10 years), or whose malignancy was a basal or squamous cell skin carcinoma. Any history of bladder cancer was an exclusion from participation. Women with a history of cervical dysplasia (CIN2 or higher) were to be excluded unless 2 consecutive normal cervical smears had subsequently been recorded prior to enrollment.
- •Impaired liver function including evidence of acute or chronic hepatitis or liver disease by medical history, clinical signs or symptoms, or laboratory results.
- •Evidence for ongoing infectious liver disease with positive hepatitis A antigen or immunoglobulin M antibody, hepatitis B surface antigen, or antibodies to hepatitis C virus. Participants with normal liver function tests and isolated positive antibodies to hepatitis B virus could have been included.
- •Known (or evidence of) infection with human immunodeficiency virus.
- •Known hemoglobinopathy or chronic anemia that required specific treatment within 5 years of the screening visit.
- •History of alcohol or drug abuse within 1 year prior to screening.
- •History of unstable major psychiatric disorders. Known or suspected allergy or hypersensitivity to thiazolidinedione agents.
- •Clinically significant abnormalities in any pre-randomization laboratory analyses that, in the investigator's opinion, comprised an undue risk with the participant's participation, or could potentially confound results of the study.
- •Unexplained hematuria (>3 red blood cells per high-powered field by urine microscopy).
- •Blood donation of ≥1 pint (0.5 liter) within the past 30 days prior to screening or plasma donation within 7 days prior to the screening visit (Visit 1).
- •Prior known or possible exposure to rivoglitazone.
- •Contraindication to treatment with pioglitazone once daily.
- •Known or suspected allergy, hypersensitivity, or intolerance to the excipients of the investigational study medication.
- •Participation in an interventional medical, surgical, or pharmaceutical study within 30 days prior to the screening visit (Visit 1).
- •Any condition or concomitant therapy that, in the opinion of the investigator, might have posed a risk to the participant or made participation not in the participant's best interest.
- •A direct or familial relationship with the Sponsor, investigator, or site personnel affiliated with the study.
研究组 & 干预措施
7
Active Comparator
pioglitazone HCl 45 mg
干预措施: metformin (Drug)
8
Placebo Comparator
matching placebo for pioglitazone
干预措施: placebo (Drug)
1
Experimental
rivoglitazone HCl 0.5mg
干预措施: rivoglitazone HCl (Drug)
1
Experimental
rivoglitazone HCl 0.5mg
干预措施: metformin (Drug)
2
Experimental
rivoglitazone HCl 1.0 mg
干预措施: rivoglitazone HCl (Drug)
2
Experimental
rivoglitazone HCl 1.0 mg
干预措施: metformin (Drug)
3
Experimental
rivoglitazone HCl 1.5 mg
干预措施: rivoglitazone HCl (Drug)
3
Experimental
rivoglitazone HCl 1.5 mg
干预措施: metformin (Drug)
4
Placebo Comparator
placebo matching rivoglitazone HCl tablets
干预措施: placebo (Drug)
4
Placebo Comparator
placebo matching rivoglitazone HCl tablets
干预措施: metformin (Drug)
5
Active Comparator
pioglitazone HCl 15 mg
干预措施: pioglitazone HCl (Drug)
5
Active Comparator
pioglitazone HCl 15 mg
干预措施: metformin (Drug)
6
Active Comparator
pioglitazone HCl 30 mg
干预措施: pioglitazone HCl (Drug)
6
Active Comparator
pioglitazone HCl 30 mg
干预措施: metformin (Drug)
7
Active Comparator
pioglitazone HCl 45 mg
干预措施: pioglitazone HCl 45 mg (Drug)
8
Placebo Comparator
matching placebo for pioglitazone
干预措施: metformin (Drug)
结局指标
主要结局
Change in A1c From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus
时间窗: Baseline up to week 2, week 4, week 6, week 8, week 10, week 12, week 16, and week 20 post-dose.
Glycosylated hemoglobin (A1c) levels and mean changes in A1c were used to measure glycemic control. A1c categorical targets are \<7.0% and \<6.5%.
次要结局
- Change in Apolipoprotein (Apo) A-I From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Change in Total Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Percent Change in Total Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Change in Total Triglycerides From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Change in Fasting Plasma Glucose From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 2, week 4, week 6, week 8, week 12, week 16, and week 20 post-dose.)
- Percent Change in Total Triglycerides From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Change in High-Density Lipoprotein Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Percent Change in High-Density Lipoprotein Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Percent Change in Apolipoprotein (Apo) A-I From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Change in Apolipoprotein (Apo) B From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Percent Change in Apolipoprotein (Apo) B From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 12 post-dose.)
- Number of Participants With Treatment-Emergent Adverse Events by System Organ Class and Preferred Term Following Rivoglitazone or Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus(Baseline up to week 26 post-dose, approximately a total of 27 weeks.)
研究者
相似试验
终止
2 期
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart FailureHeart FailureNCT06142383Novartis Pharmaceuticals136
已完成
3 期
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)Chronic Obstructive Pulmonary Disease (COPD)NCT00383435Organon and Co1,055
已完成
3 期
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)Chronic Obstructive Pulmonary Disease (COPD)NCT00383721Organon and Co1,196
已完成
3 期
Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)Chronic Obstructive Pulmonary Disease (COPD)NCT01970878Pearl Therapeutics, Inc.892
已完成
4 期
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart FailureType 2 Diabetes MellitusHeart FailureNCT02917031AstraZeneca348